CY1109509T1 - Νεα αντιγονα διαμεμβρανης του τυπου οφιοειδους εκφρασμενα σε ανθρωπινους καρκινους και χρησεις αυτων - Google Patents

Νεα αντιγονα διαμεμβρανης του τυπου οφιοειδους εκφρασμενα σε ανθρωπινους καρκινους και χρησεις αυτων

Info

Publication number
CY1109509T1
CY1109509T1 CY20091101080T CY091101080T CY1109509T1 CY 1109509 T1 CY1109509 T1 CY 1109509T1 CY 20091101080 T CY20091101080 T CY 20091101080T CY 091101080 T CY091101080 T CY 091101080T CY 1109509 T1 CY1109509 T1 CY 1109509T1
Authority
CY
Cyprus
Prior art keywords
strap
family
prostate
human
expressed
Prior art date
Application number
CY20091101080T
Other languages
English (en)
Inventor
Daniel E Afar
Rene S Hubert
Kahan Leong
Arthur B Raitano
Douglas C Saffran
Stephen Chappell Mitchell
Original Assignee
Agensys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys, Inc. filed Critical Agensys, Inc.
Publication of CY1109509T1 publication Critical patent/CY1109509T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Περιγραφόμενη είναι μία νέα οικογένεια αντιγόνων διαμεμβράνης επιφανείας κυττάρου του τύπου οφιοειδούς. Δύο από τις πρωτεΐνες σε αυτήν την οικογένεια αποκλειστικά ή κυρίως αποκλειστικά είναι εκφρασμένες στον προστάτη, καθώς επίσης καρκίνο του προστάτη και έτσι μέλη αυτής της οικογένειας έχουν οροθετηθεί "STRAP" (Serpentine TRansmembrane Antigens of the Prostate). Τέσσερεις συγκεκριμένες ανθρώπινες STRAPs περιγράφονται και χαρακτηρίζονται εδώ. Οι ανθρώπινες STRAPs δεικνύουν υψηλό βαθμό συντακτικής διατήρησης μεταξύ αυτών, αλλά δεν δείχνουν σημαντική συντακτική ομολογία προς οποιεσδήποτε γνωστές ανθρώπινες πρωτεΐνες. Το πρωτότυπο μέλος της οικογένειας STRAP, STRAP-1, φαίνεται να είναι μία πρωτεΐνη μεμβράνης τύπου IIIa που εκφράζεται κυρίως σε κύτταρα προστάτη, σε κανονικούς ανθρώπινους ιστούς. Συντακτικώς, η STRAP-1 είναι πρωτεΐνη 339 αμινοξέων που χαρακτηρίζεται από μοριακή τοπολογία έξι διαμεμβράνης πεδίων και ενδοκυτταρικά Ν-κα C-άκρα, προτείνοντας ότι αυτή είναι αναδιπλωμένη με ένα "οφιοειδή" τρόπο σε τρεις εξωκυτταρικές και δύο εσωκυτταρικές θηλιές. Η έκφραση πρωτεΐνης STRAP-1 διατηρείται σε υψηλά επίπεδα κατά την διάρκεια διαφόρων σταδίων του καρκίνου του προστάτη. Επιπλέον, η STRAP-1 είναι εντόνως υπερ-εκφρασμένη σε ορισμένους άλλους ανθρώπινους καρκίνους.
CY20091101080T 1998-06-01 2009-10-15 Νεα αντιγονα διαμεμβρανης του τυπου οφιοειδους εκφρασμενα σε ανθρωπινους καρκινους και χρησεις αυτων CY1109509T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8752098P 1998-06-01 1998-06-01
US9118398P 1998-06-30 1998-06-30
EP99955273A EP1086223B1 (en) 1998-06-01 1999-06-01 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof

Publications (1)

Publication Number Publication Date
CY1109509T1 true CY1109509T1 (el) 2014-08-13

Family

ID=26777066

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101080T CY1109509T1 (el) 1998-06-01 2009-10-15 Νεα αντιγονα διαμεμβρανης του τυπου οφιοειδους εκφρασμενα σε ανθρωπινους καρκινους και χρησεις αυτων

Country Status (13)

Country Link
US (10) US6329503B1 (el)
EP (2) EP2080802B1 (el)
JP (5) JP4855577B2 (el)
AT (1) ATE437947T1 (el)
AU (1) AU757698C (el)
CA (1) CA2328989C (el)
CY (1) CY1109509T1 (el)
DE (1) DE69941187D1 (el)
DK (1) DK1086223T3 (el)
ES (2) ES2329851T3 (el)
IL (2) IL139699A0 (el)
PT (1) PT1086223E (el)
WO (1) WO1999062941A2 (el)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20020187472A1 (en) * 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6329503B1 (en) 1998-06-01 2001-12-11 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) * 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) * 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040048798A1 (en) * 1999-06-01 2004-03-11 Raitano Arthur B. Nucleic acid and corresponding protein entitle 98P4B6 useful in treatment and detection of cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000071711A2 (en) * 1999-05-20 2000-11-30 Fahri Saatcioglu Differentially expressed genes in prostate cancer
US20060073150A1 (en) * 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
ES2340249T3 (es) * 1999-12-06 2010-06-01 Agensys, Inc. Antigenos transmembrana de tipo serpentina expresados en canceres de prostata humanos y sus usos.
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
EP1268526A4 (en) * 2000-03-24 2004-09-08 Fahri Saatcioglu NEW PROSTATE-SPECIFIC AND TESTIS-SPECIFIC NUCLEIC ACID MOLECULES, POLYPEPTIDES AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES
US7611892B2 (en) * 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7189565B2 (en) 2001-03-23 2007-03-13 Fahri Saatcioglu Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
ES2383712T3 (es) 2001-01-17 2012-06-25 Biosceptre International Limited Diagnóstico y tratamiento de cánceres y otras afecciones
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2002360670A1 (en) * 2001-12-19 2003-07-09 Wilk Patent Development Corporation Method and related composition employing nanostructures
AU2002318168B2 (en) 2002-02-25 2007-12-13 Vaxiion Therapeutics, Llc Minicell compositions and methods
WO2004016643A2 (en) * 2002-08-16 2004-02-26 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
JP5840351B2 (ja) * 2002-09-06 2016-01-06 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な９８ｐ４ｂ６と称される、核酸および対応タンパク質
EP3120861B1 (en) * 2003-11-06 2018-08-15 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
EP1742966B1 (en) * 2004-04-22 2013-11-27 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2007050415A2 (en) * 2005-10-21 2007-05-03 Medivas, Llc Poly(ester urea) polymers and methods of use
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US8067550B2 (en) * 2006-10-10 2011-11-29 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
SI2502938T1 (sl) 2006-10-27 2015-05-29 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
SG183023A1 (en) 2007-07-16 2012-08-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
CN104873982A (zh) 2007-08-17 2015-09-02 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2009033234A1 (en) 2007-09-14 2009-03-19 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
JP5951929B2 (ja) * 2007-10-03 2016-07-13 コーネル ユニヴァーシティー Ｐｓｍａ抗体を用いる増殖性障害の治療
CN101981055B (zh) 2008-01-31 2016-03-09 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
JP5701752B2 (ja) * 2008-07-04 2015-04-15 バイオセプター・インターナショナル・リミテッド 抗ｐ２ｘ７ペプチドおよびエピトープ
CA2752510C (en) 2009-02-17 2024-01-23 Neil Bander Methods and kits for diagnosis of cancer and prediction of therapeutic value
WO2011020155A1 (en) 2009-08-20 2011-02-24 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
US8772459B2 (en) 2009-12-02 2014-07-08 Imaginab, Inc. J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
ES2732021T3 (es) 2009-12-24 2019-11-20 Biosceptre Aust Pty Ltd Anticuerpos de receptores P2X7 oligoméricos no funcionales
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
NZ701208A (en) 2010-06-03 2016-05-27 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
ES2656971T3 (es) 2010-09-10 2018-03-01 Biosceptre (Aust) Pty Ltd Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7
WO2012057765A1 (en) 2010-10-28 2012-05-03 The Board Of Regents Of The University Of Texas System Recombinant anti-cd19 monoclonal antibodies
AU2015261742B2 (en) * 2010-11-12 2017-10-26 Inovio Pharmaceuticals, Inc. Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
PL3536703T3 (pl) 2010-11-12 2021-10-25 The Trustees Of The University Of Pennsylvania Konsensusowe antygeny gruczołu krokowego, kodujące je cząsteczki kwasu nukleinowego i ich zastosowania
EP3527222B1 (en) 2011-02-15 2021-04-07 Vaxiion Therapeutics, LLC Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
BR112013033974A2 (pt) 2011-07-01 2017-02-14 Biosceptre Int Ltd terapia de combinação
US20130143237A1 (en) 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
EP3858341A1 (en) 2012-11-15 2021-08-04 Endocyte, Inc. Psma ligand-containing conjugates for the treatment of prostate cancer
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
KR101782623B1 (ko) 2013-07-10 2017-09-28 서울대학교산학협력단 복합 막횡단 단백질의 세포막외 펩타이드 항원 및 그의 용도
KR101947053B1 (ko) 2013-10-18 2019-02-12 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
WO2016049214A1 (en) 2014-09-23 2016-03-31 Genentech, Inc. METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3307780A1 (en) 2015-06-15 2018-04-18 Genentech, Inc. Antibodies and immunoconjugates
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
CN109152811A (zh) 2015-12-18 2019-01-04 阿吉尔瓦克斯公司 与xCT肽相关的组合物和方法
CA3037732A1 (en) * 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
MX2019006448A (es) 2016-12-01 2020-02-05 Regeneron Pharma Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet.
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
RU2019134462A (ru) 2017-04-03 2021-05-05 Ф. Хоффманн-Ля Рош Аг Антитела, связывающиеся с steap-1
US11059901B2 (en) 2017-05-01 2021-07-13 Agilvax Inc. Compositions and methods related to xCT antibodies
AU2019269685A1 (en) 2018-05-17 2020-12-03 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
CA3104386A1 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
EA202190304A1 (ru) * 2018-07-18 2022-01-21 Эмджен Инк. Химерные рецепторы к steap1 и способы их применения

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
CA2153480A1 (en) 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
DK0914155T3 (da) * 1996-03-25 2006-06-26 Medarex Inc Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
US5859045A (en) 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
CA2261019A1 (en) * 1996-07-15 1998-01-22 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
US5824504A (en) 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
CA2271234C (en) 1996-10-15 2011-04-26 The Regents Of The University Of California Animal models of human prostate cancer progression
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
EP1630235A3 (en) * 1997-02-25 2009-05-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and method for their use
WO2000004149A2 (en) 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU731840B2 (en) 1997-02-25 2001-04-05 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
AU7592998A (en) * 1997-05-23 1998-12-11 Biogen, Inc. Modulators of tissue regeneration
ATE338117T1 (de) 1997-08-01 2006-09-15 Serono Genetics Inst Sa 5' ests für proteine, die nicht gewebespezifisch sind
EP1000148A2 (en) 1997-08-01 2000-05-17 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
JPH11164691A (ja) 1997-10-03 1999-06-22 Rikagaku Kenkyusho 胚盤胞ｃＤＮＡ
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6255049B1 (en) * 1998-02-27 2001-07-03 The Trustees Of Columbia University In The City Of New York Detection of metastatic cancer cells using PCTA-1
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US6048970A (en) * 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US6329503B1 (en) 1998-06-01 2001-12-11 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
JP2002532083A (ja) 1998-12-17 2002-10-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４７個のヒト分泌タンパク質
WO2000077021A1 (en) 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 48 human secreted proteins
US6887468B1 (en) 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
US20060073150A1 (en) 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
CA2382015A1 (en) 1999-08-17 2001-02-22 Incyte Genomics, Inc. Membrane associated proteins
GB2354821A (en) 1999-09-29 2001-04-04 Dine O Quick Threshold crossing counter
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001034802A2 (en) 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2340249T3 (es) 1999-12-06 2010-06-01 Agensys, Inc. Antigenos transmembrana de tipo serpentina expresados en canceres de prostata humanos y sus usos.
HUP0203968A3 (en) 2000-01-14 2004-09-28 Corixa Corp Seattle Compositions and methods for the therapy and diagnosis of prostate cancer
EP1572987A4 (en) 2000-02-03 2005-11-30 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
AU2001233114A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
EP1268526A4 (en) 2000-03-24 2004-09-08 Fahri Saatcioglu NEW PROSTATE-SPECIFIC AND TESTIS-SPECIFIC NUCLEIC ACID MOLECULES, POLYPEPTIDES AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES
CA2403909A1 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1358349A2 (en) 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
EP1287028A2 (en) 2000-06-09 2003-03-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002010449A2 (en) 2000-07-28 2002-02-07 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
EP1311674A2 (en) 2000-08-24 2003-05-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005506033A (ja) 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法
CA2429343A1 (en) 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
WO2002057303A2 (en) 2001-01-12 2002-07-25 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
EP1390390A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences Inc HUMAN SECRETED PROTEINS
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
US6918525B2 (en) * 2003-05-23 2005-07-19 Worktools, Inc. Spring energized desktop stapler
EP1742966B1 (en) 2004-04-22 2013-11-27 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
US7056186B1 (en) * 2005-04-06 2006-06-06 Weyenberg Karey M Cleavage-enhancing foundation garment

Also Published As

Publication number Publication date
US20070104720A1 (en) 2007-05-10
US7611904B2 (en) 2009-11-03
JP5683414B2 (ja) 2015-03-11
EP2080802B1 (en) 2017-03-29
US20100190962A1 (en) 2010-07-29
WO1999062941A8 (en) 2000-08-03
AU4326299A (en) 1999-12-20
US6887975B2 (en) 2005-05-03
JP4871341B2 (ja) 2012-02-08
CA2328989A1 (en) 1999-12-09
IL203524A (en) 2013-06-27
WO1999062941A3 (en) 2000-04-06
DE69941187D1 (de) 2009-09-10
PT1086223E (pt) 2009-11-03
US7968307B2 (en) 2011-06-28
EP2080802A3 (en) 2009-08-05
JP2002517184A (ja) 2002-06-18
US7642054B2 (en) 2010-01-05
US8414898B2 (en) 2013-04-09
US20030045682A1 (en) 2003-03-06
AU757698C (en) 2004-04-08
JP4855577B2 (ja) 2012-01-18
US6329503B1 (en) 2001-12-11
ATE437947T1 (de) 2009-08-15
JP2017079748A (ja) 2017-05-18
ES2629442T3 (es) 2017-08-09
US20100173297A1 (en) 2010-07-08
US20110318371A1 (en) 2011-12-29
JP2009106284A (ja) 2009-05-21
JP2014239695A (ja) 2014-12-25
JP2012050434A (ja) 2012-03-15
US20030055217A1 (en) 2003-03-20
WO1999062941A2 (en) 1999-12-09
ES2329851T3 (es) 2009-12-01
CA2328989C (en) 2012-02-07
AU757698B2 (en) 2003-03-06
US7928201B2 (en) 2011-04-19
US20050064445A1 (en) 2005-03-24
US7053186B2 (en) 2006-05-30
EP2080802A2 (en) 2009-07-22
JP6371362B2 (ja) 2018-08-08
IL139699A0 (en) 2002-02-10
US7166714B2 (en) 2007-01-23
US7575749B2 (en) 2009-08-18
DK1086223T3 (da) 2009-11-30
US20060147951A1 (en) 2006-07-06
EP1086223A2 (en) 2001-03-28
EP1086223B1 (en) 2009-07-29
WO1999062941A9 (en) 2000-09-14
US20050202454A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
CY1109509T1 (el) Νεα αντιγονα διαμεμβρανης του τυπου οφιοειδους εκφρασμενα σε ανθρωπινους καρκινους και χρησεις αυτων
CY1111034T1 (el) Οφιοειδη διαμεμβρανικα αντιγονα εκφραζομενα σε καρκινους ανθρωπινου προστατη και χρησεις αυτων
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
FI964766A (fi) Keuhkopintaproteiinin SP-C synteettiset peptidianalogit
DE69926647D1 (de) Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen
BR0108711A (pt) Expressão heteróloga de proteìnas de neisseria
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
ATE173155T1 (de) Mittel zur künstlichen bräunung mit verbesserter stabilität
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
CY1108603T1 (el) Συστηματα πρωτεϊνων μεταφορας λιπιδιων και η καλλυντικη δερματολογικη εφαρμογη τους
FR2649982B1 (fr) Membrane biologique artificielle
DE69535719D1 (de) Fas-antigenbindender ligand
TR200002695T2 (tr) Viral zar proteinlerdeki epitoplar ve bu epitoplara karşı yönlenmiş özel antikorlar: ev sahibi dokuda viral HCV antijenlerinin tespiti için kullanılması.
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
ATE364706T1 (de) Nukleotid- und proteinsequenz von mammastatin und anwendungsmethoden
PE92298A1 (es) Variantes de aprotinina con propiedades mejoradas
BR0012704A (pt) Anticorpos antitumor, proteìnas e usos dos mesmos
ATE329500T1 (de) Verwendung eines organspezifischen ernährungmittels
DE69634994D1 (de) Bindegewebe-wachstumsfaktor 3.
Brunisholz et al. Structural studies on the light-harvesting polypeptides of Rp. acidophila
ATE389181T1 (de) Organtransplantatenabstossung und verbundene bedingungen
BR9911388A (pt) Imunógeno de somatostatina sintético para promoção de crescimento em animais de fazenda
ES8705466A1 (es) Un metodo para la preparacion del factor nkbs regulador del cancer humano.
NO20000694L (no) Fremgangsmåte for fremstilling av kontrastmidler som i utstrakt grad er fri for bivirkninger